Physician choice

DRUG2 trials

Sponsors

Celgene, Fudan University

Conditions

Breast CancerMyelodysplastic Syndromes

Phase 2

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

Not yet recruitingNCT07353437

Fudan UniversityBreast Cancer

Start: 2026-03-31End: 2032-12-31Target: 334Updated: 2026-01-20

Phase 3

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

CompletedNCT00071799

CelgeneMyelodysplastic Syndromes

Start: 2003-11-01End: 2007-07-01Updated: 2019-10-29

Related Papers

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Blood2025-11-03

Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group

Blood2025-11-03

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Annals of Hematology2014-06-2094 citations

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

2009-02-211919 citations